Group 1 - The core viewpoint of the article is that Sihuan Pharmaceutical (00460) has announced a positive earnings forecast, expecting revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - The company's stock price increased by 3.2%, reaching HKD 77.5, with a trading volume of HKD 235 million [1] - Key factors influencing the financial performance include significant growth in the medical aesthetics business, with a year-on-year growth rate of 50%-60% [1] Group 2 - The innovative drug business is entering a harvest period, characterized by a gradual reduction in R&D expenses and a steady stream of new product approvals, leading to continuous revenue growth in this segment [1] - The decline in the generic drug business is narrowing year by year, indicating improved performance in this area [1] - The company's financial condition is robust, with ample cash reserves on the balance sheet [1]

Core Insights - The company expects to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - The financial performance during this period is influenced by several factors, including significant growth in the medical aesthetics business, the maturation of innovative drug operations, a narrowing decline in the generic drug sector, and a strong financial position with ample cash reserves [1] Group 1 - The medical aesthetics business is projected to grow at a rate of 50%-60% compared to the same period last year [1] - The innovative drug segment is entering a harvest phase, with reduced R&D expenses, a steady stream of new product approvals, and successful commercialization efforts [1] - The decline in the generic drug business is narrowing year by year [1] - The company maintains a robust financial status with substantial cash on hand [1] Group 2 - From January 2024 to July 2025, the company has received approvals for 41 new medical aesthetics and pharmaceutical products, including nine medical aesthetics products and 32 pharmaceutical products [2] - Key products include self-developed medical devices and innovative drugs, which are expected to drive future revenue and profit growth [2] - The company is confident about its future development prospects due to the simultaneous launch of numerous significant new products [2]

Group 1 - The company expects to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - Key factors influencing the financial performance include a high growth rate in the medical aesthetics business, with an increase of 50%-60% compared to the same period last year [1] - The innovative drug business is entering a harvest period, with a gradual reduction in R&D expenses and a steady stream of new product approvals contributing to revenue growth [1] Group 2 - A total of 41 new medical aesthetics and pharmaceutical products have been approved for market launch from January 2024 to July 2025, including nine medical aesthetics products and 32 pharmaceutical products [2] - The launch of multiple heavyweight new products is expected to provide strong momentum for future revenue and profit growth, instilling confidence in the company's development prospects [2]

Group 1 - The company expects to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025 [1] - Key factors influencing the financial performance include a high growth rate in the medical aesthetics business, with an expected increase of 50%-60% compared to the same period last year [1] - The innovative drug business is entering a harvest phase, with reduced R&D expenses and a steady stream of new product approvals contributing to revenue growth [1] - The decline in the generic drug business is narrowing year by year, indicating improved performance in this segment [1] - The company's financial position is robust, with ample cash reserves [1] Group 2 - From January 2024 to July 2025, the company has 41 new medical aesthetics and pharmaceutical products approved for launch, including nine medical aesthetics products and 32 pharmaceutical products [2] - Notable products include self-developed medical devices and innovative drugs, which are expected to drive significant future revenue and profit growth [2] - The company is confident about its future development prospects due to the simultaneous launch of multiple heavyweight new products [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 正面盈利預告 – 1 – (1) 醫 美 業 務 高 增 長，相 較 於 去 年 同 期 增 速 在50%–60%之 間； (2) 創 新 藥 業 務 進 入 收 穫 期，包 括 創 新 藥 研 發 開 支 逐 步 減 少，獲 批 新 產 品 持 續 湧 現，新 產 品 的 商 業 化 進 展 順 利，該 板 塊 的 分 部 收 入 持 續 增 長； (3) 仿 製 藥 業 務 的 下 跌 幅 度 逐 年 收 窄；及 (4) 本 公 司 財 務 狀 況 穩 健，賬 面 現 金 充 裕。 自 二 零 二 四 年 一 月 至 二 零 二 五 年 七 月 底，本 集 團 共 有41個醫美及醫 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 四環醫藥控股集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00460 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000, ...

港股创新药概念股盘初冲高，石药集团(01093.HK)涨超5%，亚盛医药(06855.HK)涨超4%，四环医药 (00460.HK)、丽珠医药(01513.HK)等跟涨。 ...

Group 1 - The core announcement is that the Phase III clinical study for Annelazole Sodium Enteric-Coated Tablets (brand name: Anjiuwei) for the treatment of gastroesophageal reflux disease has completed its first patient enrollment, marking the second indication expansion for this drug [1] - The study is a multicenter, randomized, double-blind, positive drug-controlled trial led by Shanghai Changzheng Hospital, with participation from 32 authoritative digestive departments, aiming to evaluate the efficacy and long-term safety of Annelazole Sodium for gastroesophageal reflux disease [1] - The study is crucial for providing key data support for the approval of this indication [1] Group 2 - Annelazole Sodium Enteric-Coated Tablets is a new generation proton pump inhibitor (PPI) developed by Xuan Bamboo Biotechnology, holding global intellectual property rights and being the first and only PPI fully developed in China [2] - It is currently the only innovative PPI in China with no approved generics, featuring advantages such as multi-enzyme and non-enzyme metabolism, as well as dual-channel excretion through the intestine and kidneys, resulting in a low risk of drug interactions [2] - A publication in June 2025 indicated that elderly patients and those with renal impairment may benefit more from Annelazole Sodium treatment for gastroesophageal reflux disease [2]

Group 1 - The core point of the news is that Sihuan Pharmaceutical's subsidiary, Xuan Zhu Bio-Tech, has completed the first patient enrollment in a Phase III clinical trial for its innovative drug, Annelazole Sodium Enteric-Coated Tablets, aimed at treating gastroesophageal reflux disease (GERD) [1] - The Phase III clinical trial is a multicenter, randomized, double-blind, positive drug-controlled study led by Shanghai Changzheng Hospital, involving 32 authoritative digestive departments from various hospitals [1] - The trial aims to comprehensively evaluate the efficacy and long-term safety of Annelazole Sodium Enteric-Coated Tablets for GERD, providing critical data support for the approval of this indication [1] Group 2 - Annelazole Sodium Enteric-Coated Tablets is a new generation proton pump inhibitor (PPI) developed by Xuan Zhu Bio-Tech, holding global intellectual property rights and being the first and only PPI fully developed in China [2] - It is currently the only innovative PPI in China with no approved generics, featuring advantages such as multi-enzyme and non-enzyme metabolism, as well as dual-channel excretion through the intestine and kidneys [2] - A publication in June 2025 indicates that elderly patients and those with renal impairment may benefit more from Annelazole Sodium treatment for GERD [2]

Core Viewpoint - The announcement highlights the completion of the first subject enrollment in the Phase III clinical study of Annelazole Sodium Enteric-Coated Tablets for the treatment of gastroesophageal reflux disease (GERD), marking a significant milestone for the company and the industry [1] Group 1: Company Developments - The Phase III clinical study aims to comprehensively evaluate the efficacy and long-term safety of Annelazole Sodium Enteric-Coated Tablets for GERD, providing critical data support for regulatory approval of this indication [1] - Annelazole Sodium Enteric-Coated Tablets is the first and only PPI (Proton Pump Inhibitor) fully developed in China, representing a significant innovation in the domestic pharmaceutical market [1] Group 2: Industry Insights - According to ZhiShi Consulting data, the number of individuals suffering from GERD in China is approximately 38.3 million in 2024, with projections to increase to 42.4 million by 2032, indicating a growing market potential for GERD treatments [1]